[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-neoplasm":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,71,107,127,187,223,247,298,327,386,416],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643642","clinical-study-of-a-new-treatment-model-for-elderly-lung-cancer-patients-100643642",false,"NCT07632664","Clinical Study of a New Treatment Model for Elderly Lung Cancer Patients","A Multicenter Clinical Study on a New Treatment Model Combining New Surgical Techniques, Perioperative Comprehensive Treatment, and Postoperative Rehabilitation for Elderly Patients With Lung Cancer","Inclusion Criteria:\n\n1. Aged ≥65 years old\n2. Pathologically confirmed non-small cell lung cancer with clinical stage eligible for curative surgical resection\n3. Complete preoperative geriatric comprehensive assessment data available\n4. Capable of finishing planned surgery and long-term follow-up\n5. Voluntarily sign informed consent form\n\nExclusion Criteria:\n\n1. History of other malignant tumors within recent 5 years\n2. Severe organic dysfunction of heart, liver, renal or respiratory system that cannot tolerate thoracic surgery\n3. Preoperative confirmed distant metastasis preventing radical resection\n4. Uncontrolled active severe infection or obvious coagulation disorders\n5. Severe psychiatric disorder or cognitive dysfunction failing to cooperate with treatment and follow-up\n6. Refuse random grouping and postoperative regular monitoring","ALL","65 Years",{"count":19,"type":20},1000,"ESTIMATED","INTERVENTIONAL",[23],"NA","This multicenter prospective clinical study focuses on elderly patients with lung cancer. We will build a standardized clinical registry database, develop perioperative risk stratification and surgical early-warning models, optimize individualized surgical regimens, construct multidisciplinary perioperative comprehensive therapy, integrated Chinese-Western medicine full-cycle management and personalized postoperative rehabilitation systems, so as to form a whole-process optimized treatment model for elderly lung cancer.",[26,27,28,29,30],"Lung Neoplasm","Thoracic Surgical Procedures","Perioperative Care","Postoperative Rehabilitation","Aged",[32],"Elderly lung cancer, Risk stratification, Multimodality therapy, Integrated Chinese and Western Medicine, Enhanced recovery after surgery","RECRUITING","2026-06-02",{"date":36,"type":37},"2026-06-08","ACTUAL",{"date":39,"type":37},"2024-08-01",{"date":41,"type":20},"2028-08-31",{"name":43,"class":44},"Peking University People's Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100576039","phase-2-substudy-01i-a-study-of-investigational-agents-in-participants-with-previously-treated-stage-iv-squamous-non-small-cell-lung-cancer-nsclc-mk-3475-01ikeymaker-u01i-100576039","NCT06780098","Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I\u002FKEYMAKER-U01I)","KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Histologically or cytologically confirmed diagnosis of Stage IV squamous non-small cell lung cancer (NSCLC)\n* Has documented disease progression per Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1), as assessed by investigator after receiving an anti-programmed cell death protein 1 (anti-PD-1)\u002Fprogrammed cell death ligand 1 (PD-L1) treatment and platinum-based chemotherapy for Stage IV disease\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)\n* Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load\n* Participants with history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements\n* Has uncontrolled or significant cardiovascular disorder\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (ie, pulmonary emboli within 3 months, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion, etc), or any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (ie, rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc), or prior pneumonectomy\n* Participants who have adverse events (AEs) (other than alopecia) due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline\n* Has clinically significant corneal disease\n* Has previously received docetaxel as monotherapy or in combination with other therapies\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known untreated central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Evidence of any leptomeningeal disease\n* Has one or more of the following indicators of interstitial lung disease (ILD)\u002Fpneumonitis: any history of ILD\u002Fpneumonitis irrespective of steroid use (except for a history of radiation pneumonitis that did not require steroids), current diagnosis of ILD, clinical or radiographic suspicion of ILD\n* Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed\n* Active infection requiring systemic therapy\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)\n* Known history of, or active, neurologic paraneoplastic syndrome\n* History of allogeneic tissue\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery or have ongoing surgical complications","18 Years",{"count":55,"type":20},144,[57],"PHASE2","Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body.\n\nStandard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may not work or may stop working to treat metastatic squamous NSCLC.\n\nResearchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells.\n\nThe main goals of this study are to learn about:\n\n* The cancer response to the study treatments compared to chemotherapy\n* The safety of the study treatments and if people tolerate them\n\nThis study is one of the substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01\u002FKEYMAKER-U01).",[26],"2026-05-21",{"date":62,"type":37},"2026-05-26",{"date":64,"type":37},"2025-05-28",{"date":66,"type":20},"2032-03-02",{"name":68,"class":69},"Merck Sharp & Dohme LLC","INDUSTRY",40,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":45},"100528353","ventilation-using-radiographic-examination-functional-lung-imaging-techniques-for-the-reduction-of-toxicity-in-functional-avoidance-radiation-therapy-100528353","NCT06159660","Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy","VENTURE","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n* Histologically proven Stage II-IV non-small cell lung cancer as determined using the IASLC International Association for the Study of Lung Cancer (IASLC) 8th edition lung cancer staging guidelines.\n* To be treated with curative intent (stage II-III) or palliative intent (stage IV) with non-SABR external beam radiotherapy (e.g. 60 Gy in 30 treatments for curative intent or 30 Gy in 5 treatments for palliative intent).\n* Pulmonary function tests within 8 weeks of registration.\n* 4DCT simulation for radiation therapy.\n* Willingness to give written informed consent.\n* Willingness and ability to comply with the study procedures and visit requirements.\n* Available for follow up for 1 year or until death, whichever occurs first.\n\nExclusion Criteria:\n\n* Prior radiation therapy to the thorax.\n* Prior surgery for this cancer.\n* Prior chemotherapy for this cancer.\n* Interstitial lung disease.\n* Pregnant women.",{"count":79,"type":20},15,"OBSERVATIONAL","The goal of this observational validation study is to determine the best implementation of fluoroscopic and CT ventilation imaging in patients having non-stereotactic ablative body radiotherapy (non-SABR) radiotherapy for stages II-IV lung cancer. The main questions it aims to answer are:\n\n* Assess the dosimetric variation in functional avoidance radiation therapy (RT) plans produced using these ventilation imaging techniques,\n* Establish a quality assurance procedure for functional lung avoidance radiation therapy, and\n* Evaluate the clinical acceptable thresholds for accuracy of the method.\n\nParticipants will:\n\nPrior to radiation therapy treatment, patients will undergo:\n\n1. A standard of care 4DCT scan for radiation therapy simulation,\n2. Pulmonary Function Tests (PFT)\n3. A 4D attenuation correction CT\n4. Breath Hold Computed Tomography (BHCT) imaging where static end-inspiration and end-expiration BHCT scans will be acquired,\n5. Nuclear medicine imaging where a Tc-99m MAA SPECT perfusion scan and a Galligas PET ventilation scan will be acquired,\n6. Fluoroscopy where 1-breath cine-fluoroscope sequences will be acquired at five different angles across the chest,\n7. A 4D Cone Beam Computed Tomography (4DCBCT) scan.\n8. Scans in points 4 to 7 above will be repeated at the end of treatment. Individual participants provide their own internal control.\n\nGalligas PET ventilation images (control) are compared with ventilation images derived from additional scans (comparator) for each participant. Tc-99m MAA SPECT perfusion images (control) are compared with perfusion images derived from BHCT scans (comparator) for each patient.\n\nThere will be no change to patient treatment and patients will be treated using a standard of care anatomical based treatment plan. The pre-treatment 4DCBCT scan is part of standard of care.",[26],[84,85,86,87,88,89,90,91,92,93,94,95,96,97],"CTVI","Computed tomography ventilation imaging","Ventilation imaging","Radiation therapy","Radiotherapy","External beam","Functional lung imaging","Pulmonary fibrosis","CTPI","Computed tomography perfusion imaging","MAA","Macroaggregated Albumin","SPECT","Single Photon Emission Computed Tomography","2026-05-15",{"date":100,"type":37},"2026-05-19",{"date":102,"type":37},"2025-02-17",{"date":104,"type":20},"2026-09-01",{"name":106,"class":44},"University of Sydney",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":45},"100336022","patient-derived-organoid-model-and-circulating-tumor-cells-for-treatment-response-of-lung-cancer-100336022","NCT03655015","Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer","Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)","Inclusion Criteria:\n\n* Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.\n* Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care\n* Any clinical stage of lung cancer\n* Adult patients ≥18 years of age\n* Able and willing to complete a questionnaire on their environmental\u002Foccupational exposures and smoking\u002Falcohol history\n\nExclusion Criteria:\n\n* At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.",{"count":115,"type":20},150,"Create a living biobank of PDOs from Stage I-III lung cancer patients.",[26],"2026-04-16",{"date":120,"type":37},"2026-04-20",{"date":122,"type":37},"2018-10-16",{"date":124,"type":20},"2029-12-01",{"name":126,"class":44},"The University of Texas Health Science Center at San Antonio",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":135,"targetDuration":137,"studyType":80,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":186},"100368284","the-momentum-study-the-multiple-outcome-evaluation-of-radiation-therapy-using-the-mr-linac-study-100368284","NCT04075305","The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study","MOMENTUM","Inclusion Criteria:\n\n* Patient is to undergo or has completed imaging or treatment procedures on an MR-Linac;\n* Patient provides written, informed consent;\n* Patient is 18 years old or older.\n\nExclusion Criteria:\n\n* MRI exclusion criteria, including\n* MRI contraindications as per usual clinical care, such as (possible) pregnancy; claustrophobia and metal or electronic implants not compatible with MRI.",{"count":136,"type":20},8000,"2 Years","The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.",[140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,26,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176],"Oncology","Breast Cancer","Prostate Cancer","Gynecologic Cancer","Brain Tumor","Brain Cancer","Gynecologic Tumor","Prostate Tumor","Prostate Neoplasm","Breast Tumor","Radiation Toxicity","Quality of Life","Rectal Cancer","Rectal Tumor","Rectal Neoplasms","Lung Cancer","Lung Tumor","Esophageal Cancer","Esophagus Cancer","Esophageal Tumor","Esophageal Neoplasm","Esophagus Tumor","Esophagus Neoplasm","Pancreatic Cancer","Pancreatic Tumor","Pancreatic Neoplasms","Head and Neck Cancer","Head and Neck Neoplasms","Head and Neck Tumor","Tumor","Neoplasms","Bladder Cancer","Bladder Neoplasm","Liver Cancer","Liver Neoplasms","Liver Metastases","Oligometastases","2026-03-03",{"date":179,"type":37},"2026-03-05",{"date":181,"type":37},"2019-02-01",{"date":183,"type":20},"2030-08-01",{"name":185,"class":44},"UMC Utrecht",18,{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":200,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":222},"100284604","veterans-affairs-lung-cancer-surgery-or-stereotactic-radiotherapy-100284604","NCT02984761","Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy","CSP #2005 - Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy Trial (VALOR)","VALOR","Inclusion Criteria:\n\nInclusion Criteria for Screening\n\n* Age 18 or older\n* Any patient with a preliminary diagnosis of stage I Non-Small Cell Lung Cancer (NSCLC), whether pathologically proven by biopsy, or highly suspicious by radiographic imaging. \\[Participants will ultimately need biopsy confirmation before enrolling\\]\n* Primary tumor size less than or equal to 5 cm by CT (may include CT images from PET\u002FCT)\n* Karnofsky performance status greater than or equal to 70\n* Participant has willingness and ability to provided informed consent for participation\n\nInclusion Criteria for Randomization\n\n* Biopsy proven non-small cell lung cancer\n* Participant's case reviewed at multidisciplinary conference\n* Tumor size less than or equal to 5cm (measured on the most recent CT images available, and may include PET\u002FCT images)\n* Tumor is equal to or greater than 1.0cm from the trachea, esophagus, brachial plexus, 1st bifurcation of the proximal bronchial tree, or spinal cord (measured on the most recent CT images available, and may include PET\u002FCT images).\n* Mandatory FDG-PET\u002FCT within 60 days of the randomization date (note: FDG-PET\u002FCT may need to be repeated prior to treatment if outside of this requirement)\n* Mandatory pathological assessment of any lymph nodes \\>10mm with a SUV \\>2.5 seen on FDG- PET\u002FCT\n* Mandatory biopsy of any additional concerning lesions seen on FDG-PET\u002FCT, to make better determination that the patient is not harboring metastatic disease or a secondary primary malignancy.\n* Pre-operative FEV1 greater than or equal to 40% of predicted value and pre-operative DLCO greater than or equal to 40% of predicted value.\n* Formally evaluated and documented by a local thoracic surgeon to be medically fit to undergo a complete anatomic pulmonary resection (wedge resection not allowed)\n* Formally evaluated and documented by a local radiation oncologist to be eligible to receive protocol-defined stereotactic radiotherapy\n* Participant willingness to be randomized\n\nExclusion Criteria:\n\nExclusion Criteria for Screening\n\n* Previously evaluated by a local thoracic surgeon and determined to be medically inoperable\n* Pathological confirmation of nodal or distant metastasis\n* Prior history of lung cancer, not including current lesion\n* Prior history of thoracic surgery or lung or esophageal cancer. \\[prior cardiac surgery acceptable\\]\n* Prior history of radiotherapy to the thorax\n* Prior history of invasive state I-III malignancy treated with surgery, radiation therapy, chemotherapy, immunotherapy, or targeted therapy in the past 2 years, excluding prostate cancer, low-risk papillary thyroid cancer (less than or equal to 1 cm), follicular lymphoma, or chronic lymphocytic leukemia.\n* Prior history of IV malignancy, excluding follicular lymphoma, chronic lymphocytic leukemia, or hormone sensitive prostate cancer confined to the pelvis.\n* Ever diagnosed with stage IV metastatic cancer of any type\n* History of scleroderma\n* Positive Pregnancy test (for women \\\u003C61 years of age or without prior hysterectomy)\n\nExclusion Criteria for Randomization\n\n* Pathological confirmation of nodal or metastatic disease",{"count":196,"type":20},670,[23],"Patients with stage I non-small cell lung cancer have been historically treated with surgery whenever they are fit for an operation. However, an alternative treatment known as stereotactic radiotherapy now appears to offer an equally effective alternative. Doctors believe both are good treatments and are therefore conducting this study to determine if one may be possibly better than the other.",[26],[201,202,203,204,170,205,206,207,208,209,88,210,211],"Carcinoma, Non-Small Cell Lung","Respiratory Tract Neoplasms","Thoracic Neoplasms","Neoplasms by Site","Lung Diseases","Respiratory Tract Diseases","Carcinoma, Bronchogenic","Bronchial Neoplasms","Radiosurgery","Radiotherapy, Image-Guided","Lung Neoplasms","2026-02-17",{"date":214,"type":37},"2026-02-19",{"date":216,"type":37},"2017-04-13",{"date":218,"type":20},"2034-03-31",{"name":220,"class":221},"VA Office of Research and Development","FED",17,{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":246},"100506552","effects-of-bright-light-exposure-combined-with-specific-exercise-training-best-program-in-patients-with-cancer-100506552","NCT05875870","Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer","Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program on Sleep-Wake Rhythm, Physical and Psychological Symptoms, and Quality of Life of Patients With Thoracic Cancer: A Series Study.","Inclusion Criteria:\n\n1. Patients with newly diagnosed primary lung cancer or esophageal cancer, from the first stage to the third stage.\n2. At least 20 years of age.\n3. Able to communicate in Mandarin Chinese or Taiwanese.\n4. Literate and free from cognitive disabilities.\n5. The attending physician agrees to participate in the study.\n6. Those who can connect to the Internet with mobile devices such as computers, mobile phones, and tablets, or those whose family members can assist in the operation.\n7. Those with Karnofsky Performance Scale (KPS) greater than or equal to 70 points.\n8. Those who are hospitalized for lung cancer or esophageal cancer lesion resection.\n\nExclusion Criteria:\n\n1. Congestive heart failure.\n2. Orthopedic diseases of the lower extremities that limit one's walking ability.","20 Years",{"count":232,"type":20},200,[23],"This study plans to investigate the effectiveness of six-week light exposure combined with an exercise training program on improving sleep-wake rhythm, physical and mental symptoms, quality of life, one-year recurrence rate, and one-year survival rate of patients with lung and esophageal cancer.",[26,236],"Esophageal Neoplasms","2026-02-13",{"date":212,"type":37},{"date":240,"type":37},"2023-07-24",{"date":242,"type":20},"2028-05-15",{"name":244,"class":245},"Taipei Veterans General Hospital, Taiwan","OTHER_GOV",2,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":16,"minAge":255,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":21,"phases":258,"briefSummary":260,"conditions":261,"keywords":272,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":297},"100499704","phase-2-determine-trial-treatment-arm-04-trastuzumab-in-combination-with-pertuzumab-in-adult-paediatric-and-teenageyoung-adult-patients-with-cancers-with-her2-amplification-or-activating-mutations-100499704","NCT05786716","DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With HER2 Amplification or Activating Mutations","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage\u002FYoung Adult Patients With Cancers With HER2 Amplification or Activating Mutations.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 04 (TRASTUZUMAB AND PERTUZUMAB) OUTLINED BELOW\\*\n\n\\*When trastuzumab- and pertuzumab-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the trastuzumab- and pertuzumab-specific criteria will take precedence.\n\nInclusion Criteria:\n\nA. Confirmed diagnosis of a malignancy harbouring HER2 amplification, or an appropriate activating mutation as defined by the MTB, using an analytically validated next-generation sequencing method.\n\n• A HER2 amplification copy number between 5-9 will require an MTB discussion. A HER2 amplification copy number ≥10 will be fast-tracked for an MTB recommendation, unless there are any patient-specific individualities (such as multiple gene amplifications) that require MTB discussion.\n\nB. Age 12 years or above.\n\nC. Women of childbearing potential are eligible provided that they meet the following criteria:\n\nHave a negative serum or urine pregnancy test before enrolment and;\n\nAgree to use one form of effective birth control method such as:\n\nI. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal):\n\nII. progestogen-only hormonal contraception associated with or without inhibition of ovulation (oral, injectable or implantable)\n\nIII. intrauterine device (IUD)\n\nIV. intrauterine hormone-releasing system (IUS)\n\nV. bilateral tubal occlusion\n\nVI. vasectomised partner\n\nVII. sexual abstinence\n\nVIII. male or female condom with or without spermicide\n\nIX. cap, diaphragm or sponge with spermicide\n\nEffective from the first administration of trastuzumab or pertuzumab (whichever is first), throughout the trial and for seven months after the last administration of trastuzumab or pertuzumab (whichever is later).\n\nD. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of trastuzumab or pertuzumab (whichever is first), throughout the trial and for seven months after the last administration of trastuzumab or pertuzumab (whichever is later):\n\n* Agree to take measures not to father children by using a barrier method of contraception (condom plus spermicide) or to sexual abstinence.\n* Non-vasectomised male patients with partners who are women of childbearing potential must also be willing to ensure that their partner uses an effective method of contraception as in C, above.\n* Male patients with pregnant or lactating partners must be advised to use barrier method contraception (e.g. condom) to prevent drug exposure of the foetus or neonate.\n\nAll male patients must refrain from donating sperm for the same period.\n\nE. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nF. ADULT PATIENTS (≥18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nG. PAEDIATRIC PATIENTS (\\\u003C18 years): Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility.\n\nExclusion Criteria:\n\nA. Diagnosis of HER2-positive early or metastatic breast cancer.\n\nB. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or within seven months following their last dose of trastuzumab or pertuzumab (whichever is later).\n\nC. Severe dyspnoea at rest due to complications of advanced malignancy or requiring supplementary oxygen therapy.\n\nD. Known hypersensitivity to trastuzumab or pertuzumab, murine proteins, or to any of the excipients.\n\nE. Patients who were administered a live, attenuated vaccine within 28 days prior to enrolment, or anticipation of need for such a vaccine during trastuzumab and pertuzumab treatment or within six months after the final dose of trastuzumab and pertuzumab.\n\nF. Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias (within three months), NYHA class III or IV congestive heart failure.\n\nLeft Ventricular Ejection Fraction \\\u003C55%.\n\nPatients with a cerebrovascular event (including stroke or transient ischaemic attack \\[TIA\\]) or cardiovascular event (including acute myocardial infarction \\[MI\\]) within three months before the first dose of trastuzumab and pertuzumab.\n\n• Patients with primary CNS tumours may be considered unless intra-tumoural bleeding has occurred within 2 weeks of the first dose of trastuzumab and pertuzumab, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nG. Prior treatment with the same class of drug unless genetic profile demonstrates a mechanism of resistance known to be potentially sensitive to trastuzumab or pertuzumab.\n\nH. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial or absorption of oral medications or that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.\n\nI. Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of trastuzumab and pertuzumab, including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided the each of the following conditions are met:\n\n* CD4 count ≥350\u002FμL;\n* undetectable viral load;\n* receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* no HIV\u002F acquired immune deficiency syndrome (AIDS)-associated opportunistic infection in the last 12 months.","12 Years",{"count":257,"type":20},30,[57,259],"PHASE3","This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other anti-cancer drugs). This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK.\n\nTrastuzumab and pertuzumab work in patients with these types of cancers which have a molecular alteration called HER2 amplification or HER2 activating mutation.\n\nInvestigators now wish to find out if it will be useful in treating patients with other cancer types which are also HER2 amplified or HER2 mutated. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[262,263,264,265,266,26,267,268,269,270,271],"Haematological Malignancy","Colorectal Neoplasms","Urinary Bladder Neoplasm","Gallbladder Neoplasms","Salivary Gland Neoplasm","Pancreatic Neoplasm","Ovarian Neoplasms","Prostatic Neoplasm","Skin Neoplasm","Solid Tumour",[273,274,275,276,277,278,279,280,281,282,283,284,285,286,287],"Adult","Antibodies, monoclonal","Cancer","Child","Molecular Targeted Therapy","Mutation","Paediatric","Pertuzumab","Precision Medicine","Rare","Receptor, ErbB-2","Targeted","Trastuzumab","Tumour-agnostic","Young adult","2025-11-25",{"date":290,"type":37},"2025-12-02",{"date":292,"type":37},"2023-03-07",{"date":294,"type":20},"2029-10",{"name":296,"class":44},"Cancer Research UK",27,{"id":299,"slug":300,"hasResults":11,"nctId":301,"briefTitle":302,"officialTitle":302,"acronym":303,"eligibilityCriteria":304,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":317,"whyStopped":4,"lastUpdateSubmitDate":318,"lastUpdatePostDateStruct":319,"startDateStruct":321,"completionDateStruct":323,"leadSponsor":325,"locationsCount":45},"100517976","role-of-cancer-associated-fibroblast-mdscs-and-immune-cell-interplays-in-the-resistance-of-non-small-cell-lung-cancer-to-anti-pd1pd-l1-therapies-100517976","NCT06024538","Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1\u002FPD-L1 Therapies","COCKPI-T","Inclusion Criteria:\n\n* consecutive patients\n* lung carcinoma surgically treated by surgery only (objectives 1a and 2), or stage III lung carcinoma treated by concomitant radiochemotherapy followed by durvalumab (maintenance) treated between September 2018 and december 2021 (objective 1b)\n\nExclusion Criteria:\n\n* patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant setting (all objectives)\n* patient with previous cancer",{"count":306,"type":20},25,"Immunotherapy have revolutionized the field of oncology, but response rates are low and all patients relapse, due to cellular and soluble immunosuppressive mechanisms. These immunosuppressive mechanisms will be better characterized and their involvement in therapeutic responses in non-small cell lung cancers (NSCLC). Indeed, large transcriptomic analysis of different subsets of immunosuppressive cells will performed, correlating them to clinical outcome in a cohort of stage III disease, treated by radiochemotherapy and immunotherapy as maintenance, and stage IV treated by immunotherapy as first-line treatment. Furthermore, we will analyse cellular mechanisms by in vitro studies, assessing the effect of immunosuppressive cells, provided by fresh tumor samples, on phenotype and functions of lung cancer cell lines. The aim of this study is to better characterize immunosuppressive landscape of NSCLC and mechanisms involved in their protumor functions.",[26,309,310],"Cancer Associated Fibroblast","Myeloid-Derived Suppressive Cells Immunosuppression",[312,313,314,315,316],"Lung cancer","Immunosuppression","Immunotherapy","Immuno-oncology","Antitumor immune escape","NOT_YET_RECRUITING","2025-07-29",{"date":320,"type":37},"2025-07-30",{"date":322,"type":20},"2025-12",{"date":324,"type":20},"2026-12",{"name":326,"class":44},"University Hospital, Bordeaux",{"id":328,"slug":329,"hasResults":11,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":333,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":21,"phases":337,"briefSummary":339,"conditions":340,"keywords":350,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":385},"100484789","phase-1-a-study-of-a-selective-t-cell-receptor-tcr-targeting-bifunctional-antibody-fusion-molecule-star0602-in-participants-with-advanced-solid-tumors-100484789","NCT05592626","A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors","A Phase 1\u002F2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule, in Subjects With Unresectable, Locally Advanced, or Metastatic Solid Tumors That Are Antigen-rich (START-001)","START-001","Inclusion Criteria:\n\n1. Participants must have histologically confirmed solid tumors that are unresectable, locally advanced, or metastatic and for which standard curative therapies do not exist or are no longer effective or have intolerable toxicities. Subjects should not have received more than three lines of prior therapies for their advanced or metastatic diseases.\n2. For Phase 1, participants must have one of the following solid tumors:\n\n   1. High mutational burden (TMB-H)\n   2. Microsatellite Instability (MSI-H)\u002FDNA mismatch repair (dMMR)\n   3. Virally associated tumors\n3. For Phase 2, participants must have one of the following solid tumors:\n\n   1. TMB-H\n   2. MSI-H\u002FdMMR\n   3. CRC (both Ras wild type and mutant)\n   4. Virally associated tumors\n   5. Metastatic triple negative breast cancer\n   6. Platinum-resistant epithelial ovarian cancer\n   7. Metastatic castration-resistance prostate cancer\n   8. Primary stage IV or recurrent non-small cell lung cancer\n   9. Immunogenic solid tumors\n\n   (Other tumor histologies may also be included in Phase 2 as additional data emerge to support their inclusion.)\n4. Symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic for ≥ 14 days, and meet the following at the time of enrollment:\n\n   * No concurrent treatment for CNS disease (e.g., surgery, radiation, corticosteroids \\> 10 mg prednisone\u002Fday or equivalent);\n   * No concurrent leptomeningeal disease or cord compression.\n\nExclusion Criteria:\n\n1. Participants with a history of known autoimmune disease with exceptions of:\n\n   * Vitiligo;\n   * Psoriasis, atopic dermatitis or other autoimmune skin condition not requiring systemic treatment;\n   * History of Graves' disease, now euthyroid for \\> 4 weeks;\n   * Hypothyroidism managed by thyroid replacement;\n   * Alopecia;\n   * Arthritis managed without systemic therapy beyond oral nonsteroidal anti-inflammatory drugs.\n   * Adrenal insufficiency well controlled on replacement therapy.\n2. Major surgery or traumatic injury within 8 weeks before first dose of study drug.\n3. Unhealed wounds from surgery or injury.\n4. Treatment with \\>10 mg per day of prednisone (or equivalent) or other immune-suppressive drugs within 7 days prior to the initiation of study drug. Exceptions may be made for patients who have had allergic reaction to iodinated contrast media. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed.\n5. Clinically significant cardiovascular\u002Fvascular disease, gastrointestinal disorders, inflammatory processes, pulmonary compromises\n6. Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug.\n7. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.\n8. Participants who are known to be human immunodeficiency virus positive or hepatitis B or C positive and have uncontrolled disease.\n9. Second primary invasive malignancy not in remission for ≥ 1 year. Exceptions include non-melanoma locally advanced skin cancer, cervical carcinoma in situ, localized prostate cancer (Gleason score ≤ 7), resected melanoma in situ, or any malignancy considered to be indolent and never required systemic therapy, with the exception of indolent lymphomas.\n10. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation).\n11. Hepatic metastases unless adequately treated, either locally (e.g., by surgery, radiofrequency ablation, or chemoembolization) or systemically or both, and stable for 3 months.",{"count":336,"type":20},365,[338,57],"PHASE1","This is an open label, multicenter, phase 1\u002F2 study to assess the safety\u002Ftolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-rich.",[341,342,343,26,204,344,345,346,170,347,348,349],"Advanced Solid Tumors","Genital Neoplasm, Female","Urogenital Neoplasms","Papillomavirus Infection","Epstein-Barr Virus Infections","Carcinoma","Vulvar Neoplasms","Vulvar Diseases","Abdominal Neoplasm",[341,351,352,353,354,355,356,357,358,359,360,314,361,166,362,363,364,365,366,367,368,369,370,371,372,373,374,375,157,171],"STAR0602","Intravenous","Antineoplastic Agents","T Cell Receptor-targeting","Bifunctional Antibody-Fusion","Specific T Cell Activator","Tumor Mutational Burden (TMB) High","Microsatellite Instability (MSI) High","Virally Associated Malignancies","Checkpoint Inhibitor Resistance","Immune Checkpoint Inhibitor Resistance","Nasopharyngeal Cancer","Non-small Cell Lung Cancer","Small Cell Lung Cancer","Biliary Cancer","Melanoma","Merkel Cell Carcinoma","Skin Squamous Cell Carcinoma","Skin Basal Cell Carcinoma","Endometrial Cancer","Colorectal Cancer","Small Bowel Cancer","Cervical Cancer","Gastrointestinal Neoplasms","Gastric Cancer","2025-07-07",{"date":378,"type":37},"2025-07-09",{"date":380,"type":37},"2023-01-04",{"date":382,"type":20},"2026-10",{"name":384,"class":69},"Marengo Therapeutics, Inc.",32,{"id":387,"slug":388,"hasResults":11,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":392,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":394,"targetDuration":396,"studyType":80,"phases":4,"briefSummary":397,"conditions":398,"keywords":403,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":45},"100485399","registry-of-the-spanish-society-of-thoracic-surgery-100485399","NCT05600569","Registry of the Spanish Society of Thoracic Surgery","Registry of the Spanish Society of Thoracic Surgery (ReSECT)","ReSECT","The inclusion criteria will depend on the section of the registry to be considered.\n\n* Personal registry: patients undergoing any type of surgical intervention.\n* Registry of surgical processes by departments: patients undergoing an anatomical pulmonary resection as the first process to be implemented at the time ReSECT is to be established.\n\nExclusion Criteria:\n\n* Patients who could reject to participate in this study.",{"count":395,"type":20},30000,"5 Years","ReSECT is a project promoted by the Spanish Society of Thoracic Surgery with the aim not only to become an indefinite, dynamic and inclusive registry, but also to establish a common structural framework for the development of future multicentre projects in the field of thoracic surgery in Spain.\n\nThe goal of this nationwide prospective observational registry is:\n\n* To develop and validate forecasting tools based on powerful computational methods with the goal of assisting in decision-making and improving quality of care.\n* To evaluate the progressive implementation of certain surgical techniques that are on the rise, new technologies and future health programs.\n* To be aware of our results as specialty and professionals and to serve as a permanent benchmarking instrument in thoracic surgery.\n\nThe first part of ReSECT, based on a personal registry design, will contemplate any thoracic surgical procedure performed by thoracic surgeons and residents in thoracic surgery in our country. Additionally, the Spanish thoracic surgery departments that voluntarily accept to collectively participate will contribute to specific surgical processes focused on certain procedures with specific objectives to be progressively implemented.\n\nThe first and only surgical process implemented since the start of the ReSECT project will focus on patients to undergo anatomical lung resection with special interest in those cases whose reason for intervention was lung cancer.\n\nThe main questions to answer in case of that first surgical process include:\n\n* What is the performance of current predictive models for perioperative and oncological outcomes in our country?\n* How could we modify previous predictive models to improve their performance?\n* What is the implementation of current guideline recommendations in our country and across institutions?\n* What is the potential impact of deviations from current recommendations?\n* What is my performance compared to the rest of the thoracic surgical departments in my country in terms of perioperative and oncological outcomes?\n\nReSECT does not consider prespecified comparison groups of patients.",[399,400,401,402,26],"Pulmonary Surgical Procedures","Thoracic Surgery, Video-assisted","Robotic Surgical Procedures","Thoracotomy",[404,405,406],"Pneumonectomy","Lobectomy","Segmentectomy","2023-10-18",{"date":409,"type":37},"2023-10-19",{"date":411,"type":37},"2023-01-01",{"date":413,"type":20},"2032-12-31",{"name":415,"class":44},"Sociedad Española de Cirugía Torácica",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":424,"targetDuration":4,"studyType":21,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":317,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":45},"100491258","hsi-for-intersegmental-plane-identification-during-sublobar-pulmonary-resections-100491258","NCT05676788","HSI for Intersegmental Plane Identification During Sublobar Pulmonary Resections","Hyperspectral Imaging for Intersegmental Plane Identification During Sublobar Pulmonary Resections in Lung Cancer Patients","HYPER-Seg","Inclusion Criteria:\n\n1. Histologically confirmed lung cancer stage I\u002FII or malignancy suspicious nodules\n2. Segmentectomy is oncologically indicated or impaired pulmonary and\u002For cardiac function prevent anatomical resection\n3. Male or female patients aged ≥ 18 years without upper age limit\n4. Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance (CrCl ≥ 50 mL\u002Fmin, Cockcroft-Gault formula)\n5. Total bilirubin ≤ 1.5 x upper limit of normal (except patients with Gilbert Syndrome (Morbus Meulengracht) in whom total bilirubin \\\u003C 3.0 mg\u002FdL is allowed)\n6. Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase)\u002Falanine aminotransferase (ALT) (serum glutamate pyruvate transaminase) ≤ 2.5 x upper limit of normal\n7. Full legal capacity\n8. Written informed consent obtained according to international guidelines and local laws\n9. Ability to understand the nature of the trial and the trial related procedures and to comply with them\n\nExclusion Criteria:\n\n1. Requirement of a lobectomy or pneumonectomy to achieve complete resection\n2. Allergy to indocyanine green or iodine\n3. Hyperthyroidism\n4. Current or planned pregnancy, nursing period (if defined as requirement of clinical routine treatment)\n5. Medical condition which poses a high risk to undergo surgery as defined by the investigator\n6. Covid19 \u002F SARS-CoV2-infection at time of screening\n7. Participation in any other interventional clinical trial within the last 30 days before the start of this trial\n8. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registry and diagnostic trials is allowed\n9. Known or persistent abuse of medication, drugs or alcohol\n10. Person who is in a relationship of dependence\u002Femployment with the coordinating investigator or the investigator",{"count":425,"type":20},50,[23],"The purpose of this study is the identification of the intersegmental plane and navigation during sublobar pulmonary resections in lung cancer using Hyperspectral Imaging, the comparison with ICG fluorescence intersegmental plane identification, and the establishment of automatic intersegmental plane navigation using machine learning strategies for intraoperative navigation.",[26,429],"Pulmonary Metastasis",[431,312,406,432,433,434],"Hyperspectral Imaging","Indocyanine green","Intersegmental plane","Machine learning strategies","2023-01-06",{"date":437,"type":37},"2023-01-09",{"date":439,"type":20},"2023-04",{"date":441,"type":20},"2027-06",{"name":443,"class":44},"LungenClinic Grosshansdorf"]